Overview
The marketing authorisation for Evarrest has been withdrawn at the request of the marketing-authorisation holder.
Evarrest : EPAR - Summary for the public
English (EN)
(514.84 KB - PDF)View
български (BG)
(597.14 KB - PDF)
español (ES)
(515.07 KB - PDF)
čeština (CS)
(578.52 KB - PDF)
dansk (DA)
(518.89 KB - PDF)
Deutsch (DE)
(516.28 KB - PDF)
eesti keel (ET)
(518.26 KB - PDF)
ελληνικά (EL)
(600.8 KB - PDF)
français (FR)
(518 KB - PDF)
hrvatski (HR)
(535.13 KB - PDF)
italiano (IT)
(514.66 KB - PDF)
latviešu valoda (LV)
(593.61 KB - PDF)
lietuvių kalba (LT)
(538.4 KB - PDF)
magyar (HU)
(571.9 KB - PDF)
Malti (MT)
(577.35 KB - PDF)
Nederlands (NL)
(514.67 KB - PDF)
polski (PL)
(576.8 KB - PDF)
português (PT)
(536.9 KB - PDF)
română (RO)
(1020.06 KB - PDF)
slovenčina (SK)
(100.5 KB - PDF)
slovenščina (SL)
(567.85 KB - PDF)
Suomi (FI)
(513.9 KB - PDF)
svenska (SV)
(514.56 KB - PDF)
Product information
Evarrest : EPAR - Product Information
English (EN)
(861.4 KB - PDF)View
български (BG)
(1.55 MB - PDF)
español (ES)
(896.44 KB - PDF)
čeština (CS)
(1.51 MB - PDF)
dansk (DA)
(813.54 KB - PDF)
Deutsch (DE)
(845.01 KB - PDF)
eesti keel (ET)
(787.41 KB - PDF)
ελληνικά (EL)
(1.55 MB - PDF)
français (FR)
(818.58 KB - PDF)
hrvatski (HR)
(898.08 KB - PDF)
íslenska (IS)
(877.78 KB - PDF)
italiano (IT)
(816.34 KB - PDF)
latviešu valoda (LV)
(1.31 MB - PDF)
lietuvių kalba (LT)
(910.1 KB - PDF)
magyar (HU)
(1.15 MB - PDF)
Malti (MT)
(1.31 MB - PDF)
Nederlands (NL)
(827.81 KB - PDF)
norsk (NO)
(860 KB - PDF)
polski (PL)
(1.32 MB - PDF)
português (PT)
(818.67 KB - PDF)
română (RO)
(934.43 KB - PDF)
slovenčina (SK)
(1.32 MB - PDF)
slovenščina (SL)
(1.25 MB - PDF)
Suomi (FI)
(923.42 KB - PDF)
svenska (SV)
(864.7 KB - PDF)
Latest procedure affecting product information: II/0027/G
15/11/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Evarrest : EPAR - All Authorised presentations
English (EN)
(456.24 KB - PDF)View
български (BG)
(496.48 KB - PDF)
español (ES)
(460.12 KB - PDF)
čeština (CS)
(486.03 KB - PDF)
dansk (DA)
(460.06 KB - PDF)
Deutsch (DE)
(459.93 KB - PDF)
eesti keel (ET)
(459.94 KB - PDF)
ελληνικά (EL)
(496.65 KB - PDF)
français (FR)
(459.86 KB - PDF)
hrvatski (HR)
(472.28 KB - PDF)
íslenska (IS)
(460 KB - PDF)
italiano (IT)
(459.91 KB - PDF)
latviešu valoda (LV)
(489.48 KB - PDF)
lietuvių kalba (LT)
(474.86 KB - PDF)
magyar (HU)
(484.42 KB - PDF)
Malti (MT)
(490.05 KB - PDF)
Nederlands (NL)
(459.69 KB - PDF)
norsk (NO)
(459.61 KB - PDF)
polski (PL)
(489.07 KB - PDF)
português (PT)
(459.81 KB - PDF)
română (RO)
(930.92 KB - PDF)
slovenčina (SK)
(29.59 KB - PDF)
slovenščina (SL)
(483.95 KB - PDF)
Suomi (FI)
(460.2 KB - PDF)
svenska (SV)
(459.88 KB - PDF)
Product details
- Name of medicine
- Evarrest
- Active substance
- human fibrinogen
- human thrombin
- International non-proprietary name (INN) or common name
- human fibrinogen
- human thrombin
- Therapeutic area (MeSH)
- Hemostasis
- Anatomical therapeutic chemical (ATC) code
- B02BC30
Pharmacotherapeutic group
Local hemostaticsTherapeutic indication
Supportive treatment in adult surgery where standard surgical techniques are insufficient (see section 5.1):
- for improvement of haemostasis.
Assessment history
Evarrest : EPAR - Procedural steps taken and scientific information after authorisation
English (EN)
(551.25 KB - PDF)View
Topics
This page was last updated on